Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Journal Guam.
Press releases published on July 8, 2025
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia
GlobeNewswire
·
July 8, 2025
Nonclinical findings provide evidence of the mechanism of action of nomlabofusp and support the potential use of skin FXN concentrations as a novel surrogate endpoint for Larimar’s planned BLA submission in Q2 2026 seeking accelerated approval BALA CYNWYD, …
CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025
GlobeNewswire
·
July 8, 2025
BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver Developing Topics (late-breaking) virtual and in-person …
Agios Appoints Dr. Jay Backstrom to Board of Directors
GlobeNewswire
·
July 8, 2025
CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the appointment of Jay Backstrom, M. …
Microbix & Bulgaria’s NCIPD Execute Supply Agreement
GlobeNewswire
·
July 8, 2025
MISSISSAUGA, Ontario and SOFIA, Bulgaria, July 08, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and the National Center for Infectious and Parasitic Diseases …
ProKidney Reports Statistically and Clinically Significant Topline Results for the Phase 2 REGEN-007 Trial Evaluating Rilparencel in Patients with Chronic Kidney Disease and Diabetes
GlobeNewswire
·
July 8, 2025
Full results from REGEN-007 are being held and will be submitted to the American Society of Nephrology 2025 Kidney Week as a late-breaking clinical trial In Group 1 (n=24), kidney function stabilized in patients randomized to receive two rilparencel …
Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)
GlobeNewswire
·
July 8, 2025
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for verekitug into third indication, strengthening pipeline …
Jade Biosciences to Participate in Two Upcoming Investor Conferences
GlobeNewswire
·
July 8, 2025
SAN FRANCISCO and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its …
Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis
GlobeNewswire
·
July 8, 2025
Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study to a Phase 2b placebo-controlled study. This is a critical step required prior to proceeding to pivotal clinical trials necessary …
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
GlobeNewswire
·
July 8, 2025
- NDA assigned a Target Action Date of February 25, 2026 - - Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical …
WeightWatchers Completes Financial Reorganization, Strengthens Leadership, and Expands Program Innovation to Support Women Through Menopause
GlobeNewswire
·
July 8, 2025
With renewed financial strength, WeightWatchers accelerates its transformation with the appointment of key executives including Dr. Kim Boyd as Chief Medical Officer The Company is advancing its first integrated women’s health initiative focused on …
WEIGHTWATCHERS SCHLIEßT FINANZIELLES RESTRUKTURIERUNGSVERFAHREN AB, STÄRKT FÜHRUNGSRIEGE UND WEITET ANGEBOT UM AUF MENOPAUSE SPEZIALISIERTES PROGRAMM AUS
GlobeNewswire
·
July 8, 2025
WeightWatchers treibt mit deutlich gestärktem finanziellen Fundament und der Ernennung wichtiger Führungskräfte, darunter Dr. Kim Boyd zur Chief Medical Officer, Wandel voran Das Unternehmen startet seine erste Initiative im Bereich Frauengesundheit, die …
Comphya Closes Oversubscribed CHF 7.5 Million Series A Round to Advance U.S. and Australian Clinical Programs Following Strong Pilot Data
GlobeNewswire
·
July 8, 2025
- IDE approval obtained; U.S. pilot study clinical site launched at Johns Hopkins - Series B round in planning to support pivotal U.S. trial - New CEO appointment signals next phase of growth and expansion LAUSANNE, Switzerland, July 08, 2025 (GLOBE …
Medicines for Poland lance un avertissement : sans usines pharmaceutiques, aucune guerre ne pourra être gagnée en Europe
GlobeNewswire
·
July 8, 2025
BRUXELLES, 08 juill. 2025 (GLOBE NEWSWIRE) -- Une analyse de l’impact de la guerre sur la disponibilité des médicaments en Ukraine aboutit à la conclusion suivante : un fonds relevant du budget de l’UE doit être créé en soutien à la production de …
Medicines for Poland gibt bekannt: Ohne pharmazeutische Fabriken wird Europa jeden Krieg verlieren
GlobeNewswire
·
July 8, 2025
BRÜSSEL, July 08, 2025 (GLOBE NEWSWIRE) -- Die Notwendigkeit, einen Fonds aus dem EU-Haushalt einzurichten, um die Produktion kritischer Arzneimittel in Europa zu unterstützen, ist eine Schlussfolgerung aus einer Analyse der Auswirkungen des Krieges auf …
UAE Approves BioAro’s Longevity+ Supplement, Signaling Major Market Potential in Global Preventive Health
GlobeNewswire
·
July 8, 2025
CALGARY, Alberta, July 08, 2025 (GLOBE NEWSWIRE) -- In a significant move that bridges biotechnology, preventive health, and global wellness trends, Canadian biotech company BioAro has announced the launch of its first nutraceutical product under its new …
الإمارات العربية المتحدة تعتمد المكمل Longevity+ من BioAro، فاتحة المجال إلى إمكانات تسويقية كبيرة في مجال الصحة الوقائية العالمية
GlobeNewswire
·
July 8, 2025
كالجاري، ألبرتا, July 08, 2025 (GLOBE NEWSWIRE) -- في خطوة مهمة تربط بين التكنولوجيا الحيوية والصحة الوقائية واتجاهات العافية العالمية، أعلنت شركة التكنولوجيا الحيوية الكندية BioAro عن إطلاق أول منتج غذائي علاجي لها ضمن خط المكملات الجديد: Longevity+™، وهي …
Vereinigte Arabische Emirate genehmigen Longevity+ Nahrungsergänzungsmittel von BioAro und signalisieren damit großes Marktpotenzial im Bereich der globalen Gesundheitsvorsorge
GlobeNewswire
·
July 8, 2025
CALGARY, Alberta, July 08, 2025 (GLOBE NEWSWIRE) -- In einem bedeutenden Schritt, der Biotechnologie, präventive Gesundheit und globale Wellness-Trends miteinander verbindet, hat das kanadische Biotechnologieunternehmen BioAro die Einführung seines ersten …
Les Émirats arabes unis approuvent le complément Longevity+ de BioAro, ouvrant la voie à un fort potentiel sur le marché mondial de la santé préventive
GlobeNewswire
·
July 8, 2025
CALGARY, Alberta, 08 juill. 2025 (GLOBE NEWSWIRE) -- Dans une avancée majeure à l’intersection de la biotechnologie, de la santé préventive et des tendances commerciales en matière de bien-être, la société canadienne de biotechnologie BioAro annonce le …
Basilea erhält im Rahmen ihrer BARDA-Vereinbarung USD 39 Mio. für die weitere Entwicklung der neuen Antipilzmittel Fosmanogepix und BAL2062
GlobeNewswire
·
July 8, 2025
Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 08. Juli 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patientinnen und Patienten zu helfen, die an schweren …
Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
GlobeNewswire
·
July 8, 2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 08, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal …